EDSA vs. PLUR, FBRX, INAB, IBIO, TRAW, PULM, NXTC, CARA, COCP, and TENX
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Pluri (PLUR), Forte Biosciences (FBRX), IN8bio (INAB), iBio (IBIO), Traws Pharma (TRAW), Pulmatrix (PULM), NextCure (NXTC), Cara Therapeutics (CARA), Cocrystal Pharma (COCP), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.
Edesa Biotech vs.
Edesa Biotech (NASDAQ:EDSA) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Edesa Biotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
Edesa Biotech has a net margin of 0.00% compared to Pluri's net margin of -4,184.28%. Edesa Biotech's return on equity of -164.32% beat Pluri's return on equity.
In the previous week, Pluri had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Pluri and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.
5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Edesa Biotech has higher earnings, but lower revenue than Pluri. Edesa Biotech is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech presently has a consensus price target of $21.00, suggesting a potential upside of 1,124.49%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Edesa Biotech is more favorable than Pluri.
Edesa Biotech received 27 more outperform votes than Pluri when rated by MarketBeat users.
Summary
Edesa Biotech beats Pluri on 9 of the 15 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Edesa Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:EDSA) was last updated on 1/21/2025 by MarketBeat.com Staff